1.Comparative analysis of clinical features and survival rate of HNPCC and sporadic colon cancer
Shengrui ZHANG ; Chunyang SUI ; Lianhe ZHAO
Journal of Medical Postgraduates 2017;30(9):963-967
Objective Different types of colon cancer have a big difference in their clinical features and prognosis.The article aimed to provide theoretical basis for the diagnosis and treatment of colon cancer patients by analyzing the differences of clinical features and survival rates between hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colon cancer.Methods Retrospective analysis was made on 22 HNPCC cases and 105 cases of sporadic colon cancer in our hospital from January 2007 to January 2012 to get the clinical features and prognosis by comparative analysis.Results Compared with sporadic group, the early onset(under 40 years) (36.37% vs 9.52%), mucinous adenocarcinoma (59.09% vs 17.14%), low differentiation (45.45% vs 16.19%), TNM stage (III+IV) (54.55% vs 26.66%), lymph node metastasis (81.82% vs 57.14%), multiple primary carcinoma (36.36% vs 7.62%) and parenteral tumor (22.73% vs 5.71%) were higher in HNPCC group, but the 5 year survival rate was lower in HNPCC group, and there were significant differences between two groups(P<0.05);but there were no significant difference in gender, tumor size, location and operation (P>0.05) between two groups.Multiple primary tumors were independent risk factors for survival in HNPCC group (P<0.05), lymph node metastasis and TNM stage were independent risk factors for survival sporadic group (P<0.05).Conclusion Compared with sporadic colon cancer, HNPCC is characterized by early onset, low differentiation, high incidence of multiple primary tumors and poor prognosis, which is of great importance to find HNPCC patients or suspicious HNPCC patients.
2.Effect of tumor-associated macrophages on malignant biological behaviors of gastric cancer MGC-803 cells
ZHANG Shengrui ; ZENG Xiandong ; SUI Chunyang ; ZHAO Lianhe
Chinese Journal of Cancer Biotherapy 2019;26(1):36-41
Objective: To investigate the effects of tumor-associated macrophages (TAM) on proliferation, migration, invation and apoptosis of gastric cancer MGC-803 cells and the possible mechanisms. Methods: Human monocyte THP-1 was cultured in vitro. After being added with PMA and IL-4, the levels of interleukin-12 (IL-12) and interleukin-10 (IL-10) in cell supernatant were detected by enzyme-linked immunosorbent assay (ELISA). MGC-803 cells at logarithmic phase and M2-type TAM cells were divided into single cell culture group, non-contact co-culture group and contact co-culture group according to different culture methods. MTT assay was used to detect the proliferation of MGC-803 cells, Transwell assay was used to detect cell migration and invasion, andAnnexin V-FITC/ PI staining flow cytometry was used to examine the apoptosis and cell cycle changes of MGC-803 cells; In addition, the mRNAand protein expressions of matrix metalloproteinase-9 (MMP-9) and MMP-2 were detected by Real-time fluorescence quantitative PCR (qPCR) and Western blotting. Results: Compared with PMA group, the level of IL-12 in cell supernatant of PMA+IL-4 group decreased significantly while the level of IL-10 increased significantly (all P<0.05), indicating THP-1 cells were successfully induced to differentiate into M2-type TAM. Compared with the single cell culture group, the non-contact co-culture group and the contact co-culture group exhibited: (1) significantly increased proliferation rate of MGC-803 cells (P<0.05); (2) increased number of migrated and invaded cells (all P < 0.05); (3) significantly decreased apoptotic rate (P<0.05); (4) increased proportion of S, G2 phase cells and decreased proportion of G1 phase cells (all P<0.05);and (5) significantly increased mRNA and protein expressions of MMP-9 and MMP-2 (all P<0.05). Conclusion: TAM can promote the proliferation, migration and invasion of gastric cancer MGC-803 cells, relieve G1 phase arrest and reduce cell apoptosis, which may be related to the up-regulation of MMP-9 and MMP-2 expression in gastric cancer cells.